“Promise of Hope” fashion show supports oncology research and clinical trials in Chicago’s Southland
WHAT
Promise of Hope Fashion Reveal charity luncheon and fashion show, to support UChicago Medicine Ingalls Memorial Hospital’s Comprehensive Community-Based Cancer Research & Oncology ProgramWHO
Ingalls Development Foundation, dignitaries and local cancer survivors/advocatesWHEN
Thursday, May 9, 10:30 a.m. – 2:00 p.m.WHERE
19110 S. Ridgeland Ave., Tinley Park, ILOTHER
Advance interviews are also available with event organizers and cancer patients; media who would like to attend the event should RSVP to [email protected]
The Ingalls Development Foundation is hosting its 26th annual Promise of Hope Fashion Reveal, benefiting UChicago Medicine Ingalls Memorial Hospital’s Comprehensive Community-Based Cancer Research & Oncology Program.
The event, which takes place Thursday, May 9, 2024, from 10:30 a.m. – 2:00 p.m. at The Odyssey in Tinley Park, will feature a preview of 2024 spring fashion trends, updates on cancer research and clinical trials, testimonials from current clinical trial patients, a silent auction, raffles and more.
The fundraiser supports UChicago Medicine Ingalls Memorial Hospital’s innovative care and support services for oncology patients, while also helping the hospital provide patients with access to advanced research therapies closer to home. At any given time, about 60 clinical trials are underway at the hospital’s Southland locations. They offer patients the opportunity to receive groundbreaking treatments that are not yet widely available.
Nationwide, the success rate for Black patient to enroll in clinical trials is less than 10%, according to the National Library of Medicine1. At UChicago Medicine Ingalls Memorial, the enrollment rate is nearly 50%, far exceeding the national average. Overcoming that disparity is critical, since it has traditionally meant that patients of color have less access to new, cutting edge treatments. It also means data collected from clinical research may not be representative of entire patient populations, which in turn gives researchers an incomplete picture of how patients respond to certain treatments.
“Fear, mistrust, cultural misunderstandings and lack of access to care are often barriers to clinical trial participation for many underrepresented populations in the United States,” said Paul Donohue, VP of Philanthropy and Community Relations. “The Ingalls Development Foundation supports the hospital’s tireless work to overcome these barriers through years of building trust by ensuring minority patients are evaluated for trials and equally represented.”
Clinical trials at the hospital’s Southland locations currently span the following areas: bladder, breast, colon/rectal, gastrointestinal, head and neck, kidney, leukemia, liver, lung, lymphoma, melanoma, multiple myeloma, ovarian, and pancreatic cancers.